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Introduction
In neurology, the establishment of stroke units has 
dramatically changed the treatment of acute stroke. 
The comprehensive stroke unit has reduced the length 
of stay in hospital and combined reduction of death 
and improved functional outcome compared to previ-
ous treatments. Stroke patients, who receive organ-
ized inpatient care in a stroke unit, are more likely to 
be alive, independent and living at home 1 year after 
the stroke.1–3
Another area, in which multidisciplinary clinics 
have been shown to be useful, is in the manage-
ment of amyotrophic lateral sclerosis where a 
number of studies have shown improved care of 
the patients.4–6
Treatment of multiple sclerosis (MS) is more complex 
than treatment of acute stroke and amyotrophic lateral 
sclerosis. MS is a disease that typically affects young 
people and has a chronic long-lasting course. Disease-
modifying therapy (DMT) has become increasingly 
multifaceted and comprises a wide range of drugs 
with different mechanism of action and adverse 
effects that need meticulous monitoring.7,8 The quick 
access to a large set of investigations, including mag-
netic resonance imaging (MRI), multimodal evoked 
potentials, optical coherence tomography, immuno-
logical tests and antibody tests, requires an advanced 
level of organization. Even symptomatic therapy has 
become more extensive, involving a wide range of 
treatments for spasticity, bladder, bowel and sexual 
disturbances, pain, fatigue and cognitive impairment.9 
It is not possible for the family physician to master the 
current treatment algorithm embracing an increasing 
number of disease-modifying drugs, and not even the 
general neurologist giving care to only a few patients 
with MS will acquire the expertise necessary to pro-
vide the gold standard of therapy in patients with 
therapeutically complicated MS.
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Patient population and needs
There are many reasons why we need to promote 
worldwide the concept of MS Care Unit, summarized 
in Table 1. 
Our knowledge of the current treatment of MS across 
the European countries is insufficient. The European 
MS Platform (EMSP) has performed a mapping of 26 
MS registries in Europe in spring 2017 and demon-
strated the currently existing fragmentation in data 
collection and data analysis; in most registries and 
cohorts, the neurologist alone is filling in patient data.
The quality of health care varies according to European 
nations, regions and settings (http://www.emsp.org/
wpcontent/uploads/2015/08/MS-in-EU-access.pdf). 
Different studies have been reported focusing on col-
lecting and publishing report data on the quality of the 
health care models. Although the studies made the 
above data increasingly available to the public, more 
studies are needed to evaluate patients’ perspective on 
MS care models. Since the ultimate goal of the multi-
disciplinary MS Care Unit approach is to increase 
patient satisfaction and quality of life (https://www.
msif.org/living-with-ms/what-influences-quality-of-
life/seven-principles-to-improve-quality-of-life/), core 
and transversal to the implementation of the above 
approach is the development of an effective framework 
to enable people with MS engagement and activation.
A recent study analysed responses from MS neurolo-
gists in several European countries regarding choice 
of therapy to various clinical situations. The treatment 
choices varied considerably, even in countries with 
the same access to all approved drugs for treatment of 
relapsing-remitting MS.10 Early treatment and per-
sonalized approach are considered as two fundamen-
tal steps for the success of DMTs in MS, both are 
linked to the definition of various clinical and 
laboratory prognostic and predictive factors,7,11 easily 
available in well-organized clinical centres only. 
Accurate monitoring of the treatment response and a 
quick shift to an alternative DMT can only be possible 
if the contact of the patient with the treating neurolo-
gist is facilitated by an appropriate assistance setting, 
including some recent technical developments, such 
as remote control by wearable devices. Approval of 
new DMTs is usually associated with post-marketing 
studies to a better definition of the safety/efficacy pro-
file. Databases and registries are used to provide this 
type of information; however, the quality of these 
tools is essential and again depends on the MS centre 
organization.12
MS affects several body systems and patients invaria-
bly require specialized interdisciplinary support. Both 
patients with relapsing and progressive forms of MS 
may benefit from a multidisciplinary approach.13 The 
MS neurologist and MS specialist nurse are the key 
persons in the management of all patients with MS.
Patients with an Expanded Disability Status Scale 
(EDSS) score of 0–3 are usually managed as outpa-
tients, and the main mission in these patients is to pro-
vide adequate treatment with disease-modifying 
drugs. Mild impairment tends to require specific man-
agement of symptoms such as spasticity, urinary dis-
orders or mild gait/posture disturbances. Fatigue is a 
common complaint even at lower level of disability. 
Collaboration with external therapists may provide 
encouragement for patients to maintain regular physi-
cal activities.
In patients with greater degree of disability (EDSS 
score: 3–6), management involves a multidisciplinary 
team consisting of a physiotherapist, speech therapist, 
occupational therapist and neuropsychologist. Close 
collaboration with external social care services is 
required to maintain the working ability of the patient 
and connection to the labour market.
Table 1. Why we need comprehensive MS Care Unit to optimize treatment.
• Disease and treatment complexity
• Early diagnosis
• Shortage of MS neurologists
• Selection of treatment strategies
• Offer timely the entire spectrum of interventions
• Patient involvement in the process of decision making
• Appropriate monitoring
• Risk minimization
• Integration of competences
• Continuity of the assistance
• Contribution to the post-marketing refinement of drug profile
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The major intervention in patients with an EDSS 
score >6 remains the management of the many 
symptoms and neurological deficits that are the result 
of the progressive clinical phenotype.14 The main 
goals of physical therapy and rehabilitation are to 
maintain patients’ autonomy and quality of life at 
home and to avoid complications to the MS disease. 
Management tends to focus largely on physiotherapy 
and occupational therapy aiming primarily on disa-
bility compensation, but also towards functional 
recovery, so that patients can continue with their 
activities. The majority of patients with high EDSS 
scores require technical aids, such as a wheelchair, 
crutches and ankle foot orthoses, and are reliant on 
considerable support from their carers. Several stud-
ies consistently indicated the need for MS patients to 
have psychosocial support.15,16
The proportion of patients using inpatient, outpatient 
and social care increases with the degree of disease 
severity. A Swedish study analysed the use of health, 
social and informal care services and satisfaction with 
care in a population-based sample of people with MS 
in Stockholm County.16 During a 3-year period, 92% 
had been in contact with a neurology outpatient clinic. 
Over two-thirds had been in contact with other hospi-
tal outpatient departments; the most frequently used 
was departments of urology. There were no signifi-
cant differences among patients with various disease 
severities (EDSS) regarding the proportion using out-
patient care at departments of neurology. The great 
majority of MS patients used hospital specialist care 
and primary care in parallel, with many departments 
and services involved.
At least in some countries, there is still an unmet need 
for physiotherapy, occupational therapy, equipment 
and aids, together with social, financial and employ-
ment unmet needs. Overall, the unmet needs were 
more frequent in patient with progressive MS.17,18
Ongoing initiatives
The Multiple Sclerosis International Federation 
(MSIF) movement’s new strategy, 2017–2021, identi-
fied the potential for good quality, rigorous patient 
data and analysis to speed up discoveries in MS 
research, inform decisions made by all the health 
workers and the other stakeholders involved and ulti-
mately improve outcomes for people living with MS. 
To meet the above need, in 2017 MSIF launched an 
international collaborative initiative, which will 
engage and commit experts from around the world, 
and is led by the Italian MS Society, with the overall 
goal to identify and define the functional domains that 
matter most to people with MS and develop research-
based methods to be used in MS Care decision-mak-
ing processes, in data sharing and ultimately in 
regulatory decision-making.
There are currently different ongoing actions of the 
MS Care Unit. The MS Brain Health initiative is in 
the process of doing a Delphi survey to define by con-
sensus the metrics that the wider MS community need 
to measure how they are functioning against interna-
tionally defined quality standards.
Within the frame, the importance of patient activation 
programmes in MS management has been recently 
discussed in a review that reflects the content of the 
presentations, audience polling results and discus-
sions of the second Pan-European MS Multi-
stakeholder Colloquium.19 It was proposed that 
evidence-based care practice guidelines for MS 
should be developed at the European level (http://
www.eurims.org/News/recommendations-on-rehabil-
itation-services-for-persons-with-multiple-sclerosis-
in-europe.html). These guidelines would supplement 
the European Committee for Treatment and 
Research in Multiple Sclerosis (ECTRIMS)–
European Academy of Neurology (EAN) Clinical 
Practice Guideline on Pharmacological Management 
of Multiple Sclerosis.
The MS Care Unit
According to the recent ECTRIMS-EAN guidelines 
for treatment of MS, the entire spectrum of disease-
modifying drugs should only be prescribed in centres 
where there is an adequate infrastructure to provide 
proper monitoring of patients, comprehensive assess-
ment, and detection of side effects and ability to 
promptly address them.20
In some countries (e.g. Canada), certain MS drugs are 
marked ‘XX®’ and should only be prescribed by neu-
rologists, who are experienced in the treatment of 
MS, are knowledgeable of the efficacy and safety pro-
file of XX and are able to discuss benefits/risks with 
patients. This condition will of course always be 
accomplished of a multifocal MS Care Unit.21
A multidisciplinary MS Care Unit approach can be 
defined as the presence of a group of different special-
ists, who work together and with the MS neurologists 
and nurses with a formalized diagnostic workup pro-
cedure, protocols for initiation and follow-up of 
DMTs and management of complications. The MS 
Care Unit should offer availability of a specific single 
contact neurologist and nurse, who can provide 
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information, support and advice to the individual MS 
patients. This is imperative as a recent study on the 
effect of organizational features on patient satisfac-
tion with care in Italian MS centres clearly showed 
that patient satisfaction was inversely associated with 
hospital size, probably because larger hospital may 
have failed in building an individualized relationship 
between patients and the MS neurologist and nurse 
and tailoring the communication of information.22
The premises of the MS Care Unit should comprise an 
outpatient clinic with consulting/examining rooms, 
rooms for procedures, for example, lumbar puncture 
and filling of intrathecal baclofen pumps, and a dedi-
cated quiet room or area, free from distraction or 
interruption, where patients receive information about 
their disease. Ideally, the MS Care Units should have 
their own infusion centre and other spaces dedicated 
to other professionals. In addition, the MS Care Unit 
should have inpatient facilities or have access to 
admission of patients to a department of neurology 
with well-designed care for MS patients.
Organization of the MS Care Unit
The core of the MS Care Unit is the patients and 
would in addition to MS neurologists and nurses 
comprise (at least three of) neuropsychologists, 
clinical psychologists, physiotherapists, occupa-
tional therapists, speech therapists, social workers 
and secretaries, and the multidisciplinary MS clinic 
should offer specialist services in dietary matters, 
and in the treatment of spasticity, incontinence and 
pain. Some of these services may, however, be pro-
vided by a MS neurologist or MS nurse in the MS 
Care Unit with special education and interest 
(Figure 1).
In patients with relapsing forms of MS, the correct 
diagnosis and DMT should be secured by the neurolo-
gists in the MS Care Unit, who have special interest in 
MS, and who use the majority of their clinical work-
ing hours with treatment of MS patients. Together 
with the MS specialist nurses, these neurologists con-
stitute the backbone of the health care persons in the 
MS Care Unit.
The multidisciplinary MS Care Unit should collabo-
rate with a pharmacist with special knowledge of MS 
therapies and be able to offer the full range of 
approved DMTs for relapsing and progressive MS 
and to tailor the treatment to the single patient’s need. 
In addition to personalized therapy using drugs 
licenced for the treatment of MS, the MS Care Unit 
should have a variety of experimental therapies at dis-
posal of patients with therapeutic refractory MS. This 
approach requires specially trained MS neurologists 
and MS nurses.21
The neuropsychologist is essential for the assessment 
of neuropsychological problems that in MS patients 
can be classified into three broad categories: cogni-
tion, mood disorders and behavioural symptoms. 
Irrespective of the severity of the deficits, it is impor-
tant to diagnose all cases of cognitive impairment and 
to monitor its evolution at regular neuropsychological 
assessment by a neuropsychologist or an occupational 
therapist supervised by a neuropsychologist (e.g. at 
the start of and during immunotherapy, and in the 
event of worsening). Cognitive rehabilitation may 
keep the mildly cognitive MS patient able to maintain 
working and the more progressed patients able to stay 
in their own homes.
In patients with moderate or more pronounced disabil-
ity, the mainstay of treatment for both weakness and 
spasticity is physical therapy and exercise.23 Hence, 
physiotherapists constitute an essential group in the 
multidisciplinary MS Care Unit, and they should have 
a strong collaboration with physiotherapists in reha-
bilitation clinics and in the primary health sector.
Occupational therapists may be an integrated part of 
the multidisciplinary MS Care Unit or can be associ-
ated to the unit. The majority of patients with high 
EDSS scores require technical aids in order to main-
tain independence and ability of staying in their own 
homes. Usually, the occupational therapist works in 
close collaboration with the physiotherapist and the 
neuropsychologist.
Patients with speech difficulties may benefit greatly 
when their deficits are managed by a speech therapist 
who usually is an external collaborator in smaller 
clinics.
The whole neurorehabilitation team in the multidisci-
plinary MS Care Unit liaises regularly with the patient’s 
external therapist to encourage and facilitate mainte-
nance of physical and social activities. Collaboration 
with external neurorehabilitation institutions is impor-
tant in relation to patients who are in need of longer 
inpatient rehabilitation stay.
The clinical psychologist may facilitate the develop-
ment of effective communication and relationship 
between the clinician and the patient, which may sig-
nificantly increase MS patients’ satisfaction with 
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healthcare. In relation to adaption to the new life situ-
ation after having the diagnosis of MS and when dete-
rioration of health occurs, the accessibility to 
psychological support and crisis therapy is essential. 
Effectively, the National Institute for Health and Care 
Excellence (NICE) guidelines recognize that psycho-
logical support should be routine in the management 
of patients with MS (NICE 2003 and NICE 2014).24,25
The medical social worker or counsellor is important 
offering advice on social security matters to MS 
patients at different stages of the disease course and is 
mediator of social care and home care services deliv-
ered by the public social services departments. These 
services include home help, personal assistants, trans-
portation, physiotherapy and technical aids such as a 
crutches and other walking aids, wheelchair and mini 
crossers.
The personnel of multidisciplinary MS Care Unit 
should be able to offer expertise in treatment of spas-
ticity, incontinence and pain and to give advice on 
dietary aspects, conveyed by specially educated MS 
neurologists or MS nurses with special interest in the 
topic, and for matters that are not mastered by the 
personnel in the MS Care Unit, connection and 
collaboration with external specialists should be 
established.
The role of the general practitioner in the manage-
ment of MS patients vary considerably between coun-
tries in Europe, and in countries in which the family 
physician is much involved, the team in the multidis-
ciplinary MS Care Unit should keep a close collabo-
ration with the patients’ general practitioner.
In many countries, practicing neurologists are respon-
sible for management of the majority of people with 
MS. The multidisciplinary MS Care Unit should offer 
collaboration on second opinion of patients with diag-
nostic challenges and assist in the treatment of patients 
with aggressive MS course and of patients not 
responding to conventional therapies.
The fully developed integrated multidisciplinary MS 
Care Unit encompasses staff members with many dif-
ferent skills, including occupational therapist, speech 
therapist, dietician, medical social worker or counsel-
lor, clinical psychologist, laboratory technician and 
specialists in treatment of spasticity, incontinence and 
pain, who may be members of the multidisciplinary 
team, may be MS neurologists or MS nurses, with spe-
cial expertise or may be external experts collaborating 
closely with the staff of the MS Care Unit (Figure 2).
Some neighbouring specialities are extremely impor-
tant collaborators such as neuro-radiologists, neuro-
ophthalmologists and urologist.
A reliable and expert neuro-radiological service is of 
paramount importance for the diagnostic workup of 
patients suspected of MS and for monitoring the dis-
ease evolution and response to DMT as well as adverse 
effects to therapy. Several large multidisciplinary MS 
Figure 1. Minimum requirements for a multidisciplinary MS Care Unit.
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Care Units have special MS MRI facilities closely col-
laborating with or embedded in the unit.
Collaboration with neuro-otologist is important in the 
treatment of patients with vertigo or balance prob-
lems, and neurophysiologists are often responsible for 
performance of visual, somatosensory and motor-
evoked potentials that are a part of the diagnostic 
workup in some patients.
Psychiatric comorbidities are common in MS patients 
and also require special care.26 Every phase of MS can 
lead to initial denial and later acceptance phases that 
can be handled appropriately by psychotherapy. Many 
of these symptoms can be managed by the personal of 
the MS Care Unit, but in some cases, the choice of 
antidepressant or initiation of neuroleptics will need 
discussion with psychiatrists.
Collaboration with other specialities, for example, 
internal medicine specialists, endocrinologist, rheu-
matologists, specialists in infectious diseases and car-
diologists is necessary, not only to treat complications 
of the MS disease but also to manage comorbidities.
Spasticity is in generally handled by the neurologists 
in the MS Care Unit with pharmacological treatment 
and botulinum toxin injected locally, but when severe 
spasticity in the legs requires intrathecal baclofen 
administration, a multidisciplinary approach is 
needed, including collaboration with neurosurgeons.
Tremor can be one of the most disabling symptoms of 
MS that in many cases do not respond satisfactorily to 
pharmacotherapy and, hence, requires either the use 
of assistive devices or surgical intervention such as 
deep brain stimulation. The decision for particular 
therapeutic measures may be reached by a team that 
includes expert neurologists, neurosurgeon, psychia-
trist and psychologist.
For treatment of spasticity complications such as 
joint contractures, hip dislocations, scoliosis and 
deformed extremities, collaboration with orthopae-
dics is required, as well as for treatment of fractures 
caused by the falls that frequently occurs in disabled 
MS patients.
Other surgical interventions are required in refractory 
and more severe cases of bladder dysfunction where 
enterocystoplasty (Bricker) and urinary diversion 
become alternative treatment modalities, and in cases 
of severe swallowing disorders where gastrostomy 
may be needed.
The fully developed integrated multidisciplinary MS 
Care Unit will usually be connected to a clinical trial 
unit and a MS research unit with laboratory facilities.
Figure 2. Organization of the fully developed integrated multidisciplinary MS Care Unit.
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Patients’ perspective
A multidisciplinary clinical approach that integrates 
patient-care (diagnosis, treatment and follow-up) and 
rehabilitation activities (including neuropsychologi-
cal and social support) would enhance the efficacy of 
therapy (all aspects including compliance and adher-
ence and not only limited to effectiveness) and pro-
vide better patient overall satisfaction.27 The 
availability of a specific single contact neurologist 
and nurse, who can provide information, support and 
advice to the individual MS patient, is a major advan-
tage over a regular outpatient clinic. Patients may be 
exposed to a variety of experimental therapies, which 
may not be available to office-based neurologists.
Accompanying acceptance of the need to integrate 
patient perspectives is an increase in the demand for 
research-based methods and tools to measure the 
effectiveness of incorporating patient input into the 
MS care models and, ultimately, its impact on patients’ 
health and quality of life.28 Given the plethora of 
functional domains affected in patients with MS, a 
multidisciplinary care team, such as the one described 
in this paper, is needed in order to improve MS 
patients’ quality of life.29
Rehabilitation is essential in the management of the 
MS patient during the patient journey along the course 
of MS.14 The rehabilitation physician could be 
included in the core team of the MS Care Unit and be 
working together in a team with physiotherapist, 
speech therapist and occupational therapist that could 
deliver appropriate neurorehabilitation treatment.
Why are multidisciplinary MS Care Units 
important?
DMT has become increasingly complex and com-
prises a wide range of drugs with different mechanism 
of action and adverse effects that need meticulous 
monitoring.7,8 The establishment of multidisciplinary 
MS Care Units would facilitate timely and correct 
treatment and increase the safety for patients treated 
with DMTs. The use of the entire therapeutic arma-
mentarium seamlessly and correctly requires expert 
neurologists and MS nurses.
The presence of several MS expert neurologists in the 
MS Care Unit enables ad hoc real-time conferences 
about patients presenting with diagnostic or therapeu-
tic challenges.
In almost all countries, there is a shortage of MS neu-
rologists and multidisciplinary MS Care Units offer 
the possibility of transfer of tasks from neurologists to 
MS nurses or therapists and thereby release neurolo-
gist time to patient contact. NICE has recommended 
that care for people with MS should comprise a coor-
dinated multidisciplinary approach (NICE 2003).24 
Management of people with MS should involve pro-
fessionals who can best meet the needs of the person 
with MS and who have expertise in managing MS 
including consultant neurologists, MS nurses, physio-
therapists and occupational therapists, speech and lan-
guage therapists, psychologists, dieticians, social care 
and continence specialists, and general practitioners.
However, it is not realistic that every patient is man-
aged in integrated MS care centres all over Europe, 
and the approach has to be balanced with clinical 
practice. Hence, in many countries, although it should 
be encouraged to treat as many people with MS in MS 
Care Units, collaboration between the MS Care Units 
and practicing neurologist needs to be established 
with the MS Care Unit offering the function as refer-
ence centres.
Uygunoglu et al.30 have reviewed the reasons for pro-
moting integrated multidisciplinary clinics focusing 
primarily on patients with progressive forms of MS. 
They concluded that the optimum care for patients 
with MS requires a multispecialist work force which 
should include not only expert neurologists but also 
physical medicine and rehabilitation physicians, 
physiotherapists, speech therapists, neuro-urologists, 
psychiatrists and psychologists, sleep medicine spe-
cialists, specialist MS nurses, social workers, occupa-
tional therapists and optional others.
However, Papeix et al.31 found in a small randomized 
controlled trial that an integrated multidisciplinary 
approach was not superior to usual multidisciplinary 
care in promoting quality of life as measured by the 
MS impact scale-29. They suggested that in order to 
enhance the efficacy and to provide better patient sat-
isfaction, the MS nurse specialist should, as part of 
their work, be involved in ensuring that the chain of 
multidisciplinary assessments and interventions is 
organized systematically and that all patients can 
access the necessary experts.32
How should the efficacy of the 
multidisciplinary MS Care Unit approach be 
measured?
As the MS Care Unit approach advances, there 
remains a need to identify, define and capture the 
return of investment across key stakeholders, such as 
payers, hospital systems and providers, as well as 
returns experienced by patients. All stakeholders will 
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look for short-term returns on their investment of 
money, time and effort in order to maintain the 
momentum. The MS Care Unit approach will apply a 
prospective model engaging stakeholders in defining 
metrics to measure its impact (co-accountability 
model), rather than using a single performance assess-
ment system (top down accountability approach). 
Within this frame, in measuring the impact of MS 
Care Unit, it will be fundamental to consider patients 
and their needs and perspectives as key stakeholders 
throughout the entire measurement process. The 
measures of effects of the establishment of multidisci-
plinary MS Care Units are given in Table 2. 
One of the first successes of the initiative will be the 
establishment of multidisciplinary MS Care Units in 
many countries, which could be documented in a sur-
vey conducted by the European Charcot Foundation, 
and for which to develop the relevant co-accountability 
model to measure the impact on patients and society.
In Denmark, the initiative has resulted in political 
plans to establish multidisciplinary MS Centres.
It is, however, difficult to provide a universal measure 
of the efficacy of the multidisciplinary MS Care Unit 
because of the considerable variations in treatment 
choices in specific patient situations shown to exist 
across different countries,10 but a more uniform choice 
of treatments according to published international 
guidelines after establishment of MS Care Units, shown 
in a similar survey, would confirm beneficial effect.
The ultimate goal of the multidisciplinary MS Care 
Unit approach is to increase patient satisfaction and 
quality of life. Hence, a better quality of life measured 
on a recognized quality-of-life scale or visual analogue 
scale should indicate a high patient satisfaction.
It is obvious that the terms of performance of different 
MS Care Units vary across regions and countries. 
Hence, the criteria that can define the performance of 
good quality of an MS Care Unit will need to be 
defined according to local conditions.
Establishment of MS Care Units may even be cost-
effective for the society, reducing claims for disability 
benefit by maintaining the working ability of people 
with MS and reducing the costs of home help and cus-
todial care by keeping people with MS resourceful. 
This would, however, due to the diverse course of MS 
and complexity of management be difficult to docu-
ment on the short run and will require socio-economic 
studies with long-term observation.
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Table 2. Measures of effects of the establishment of multidisciplinary MS Care Units.
Short-term measures
• More uniform choice of therapies in line with published international treatment guidelines
• Better quality of life measured on a recognized quality-of-life scale or visual analogue scale
• More seamless care of people with multiple sclerosis
• Regularly repeated data analysis of a minimal set of PRO(M)s, which will be agreed by and implemented into all 
willing MS registries globally
• Regularly repeated analysis of a European minimal data set of RWE data (beside the PROs) which will be agreed 
by and implemented into all willing MS registries Europe wide
Long-term measures
• Improved therapeutic effectiveness of disease-modifying therapy – measured using big data from several MS 
registries
• Increased safety for patients on disease-modifying therapy – measured by prospectively collected safety data 
reported to EMA by European MS registries
• Reducing claims for disability benefit
PRO(M): patient-reported outcome (measure); RWE: real-world evidence; EMA: European Medicines Agency.
PS Sorensen, G Giovannoni et al.
journals.sagepub.com/home/msj 635
Genzyme, Genentech, GlaxoSmithKline, Merck-
Serono, Novartis, Roche, Synthon BV and Teva. X.M. 
has received speaking honoraria and travel expenses 
for participation in scientific meetings, has been a 
steering committee member of clinical trials or par-
ticipated in advisory boards of clinical trials in the 
past years with Actelion, Almirall, Bayer, Biogen, 
Celgene, Genzyme, Merck, Novartis, Oryzon 
Genomics, Roche, Sanofi Genzyme and Teva 
Pharmaceutical. C.T. has, in his capacity as consultant 
for EU health affairs, received consultancy fees by 
Gruenenthal and by PharmaGenesis. In his capacity 
as Director External Affairs of the European MS 
Platform, he served in advisory boards and/or work-
shops by Biogen, Merck, Novartis, Sanofi Genzyme, 
Servier and Takeda. His employer, the European MS 
Platform, has received unrestricted project grants 
from Actelion, Almirall, Bayer, Biogen, icometrix, 
MedDay, Merck, Mylan, Novartis, Roche, Sanofi 
Genzyme, SCA, Servier, Synthon, Terumo and Teva. 
P.Z. has no conflict of interest to declare. G.C. has 
received personal compensation, outside this work, 
for participating in scientific advisory boards and for 
speaking activities from Novartis, Teva, Sanofi 
Genzyme, Biogen, Roche, Almirall, Celgene, Forward 
Pharma, MedDay and Excemed.
Funding
The author(s) received no financial support for the 
research, authorship and/or publication of this article.
References
 1. Stroke Unit Trialists’ Collaboration. Organised 
inpatient (stroke unit) care for stroke. Cochrane 
Database Syst Rev 2013; 9: CD000197.
 2. O’Rourke K and Walsh C. Impact of stroke units on 
mortality: A Bayesian analysis. Eur J Neurol 2010; 
17: 247–251.
 3. Chan DK, Cordato D, O’Rourke F, et al. 
Comprehensive stroke units: A review of comparative 
evidence and experience. Int J Stroke 2013; 8: 
260–264.
 4. Traynor BJ, Alexander M, Corr B, et al. Effect of a 
multidisciplinary amyotrophic lateral sclerosis (ALS) 
clinic on ALS survival: A population based study, 
1996–2000. J Neurol Neurosurg Psychiatry 2003; 74: 
1258–1261.
 5. Rooney J, Byrne S, Heverin M, et al. A 
multidisciplinary clinic approach improves survival 
in ALS: A comparative study of ALS in Ireland and 
Northern Ireland. J Neurol Neurosurg Psychiatry 
2015; 86: 496–501.
 6. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice 
parameter update: The care of the patient with 
amyotrophic lateral sclerosis: Multidisciplinary care, 
symptom management, and cognitive/behavioral 
impairment (an evidence-based review): Report of 
the Quality Standards Subcommittee of the American 
Academy of Neurology. Neurology 2009; 73: 
1227–1233.
 7. Comi G, Radaelli M and Soelberg Sorensen P. 
Evolving concepts in the treatment of relapsing 
multiple sclerosis. Lancet 2017; 389: 1347–1356.
 8. Soelberg Sorensen P. Safety concerns and risk 
management of multiple sclerosis therapies. Acta 
Neurol Scand 2017; 136: 168–186.
 9. Thompson AJ, Toosy AT and Ciccarelli O. 
Pharmacological management of symptoms in 
multiple sclerosis: Current approaches and future 
directions. Lancet Neurol 2010; 9: 1182–1199.
 10. Fernandez O, Delvecchio M, Edan G, et al. Survey 
of diagnostic and treatment practices for multiple 
sclerosis in Europe. Eur J Neurol 2017; 24: 
516–522.
 11. Kalincik T, Manouchehrinia A, Sobisek L, et al. 
Towards personalized therapy for multiple sclerosis: 
Prediction of individual treatment response. Brain 
2017; 140: 2426–2443.
 12. Trojano M, Tintore M, Montalban X, et al. Treatment 
decisions in multiple sclerosis – Insights from real-
world observational studies. Nat Rev Neurol 2017; 
13: 105–118.
 13. Clavelou P. Can we optimize our teams? 
Multidisciplinary care for multiple sclerosis. Expert 
Rev Neurother 2013; 13: 39–44.
 14. Feinstein A, Freeman J and Lo AC. Treatment of 
progressive multiple sclerosis: What works, what 
does not, and what is needed. Lancet Neurol 2015; 
14: 194–207.
 15. Ytterberg C, Johansson S, Andersson M, et al. 
Variations in functioning and disability in multiple 
sclerosis. A two-year prospective study. J Neurol 
2008; 255: 967–973.
 16. Gottberg K, Einarsson U, Ytterberg C, et al. Use 
of health care services and satisfaction with care in 
people with multiple sclerosis in Stockholm County: 
A population-based study. Mult Scler 2008; 14: 
962–971.
 17. Lorefice L, Mura G, Coni G, et al. What do multiple 
sclerosis patients and their caregivers perceive as 
unmet needs? BMC Neurol 2013; 13: 177.
 18. Lonergan R, Kinsella K, Fitzpatrick P, et al. 
Unmet needs of multiple sclerosis patients in the 
community. Mult Scler Relat Disord 2015; 4: 
144–150.
Multiple Sclerosis Journal 25(5)
636 journals.sagepub.com/home/msj
 19. Feys P, Giovannoni G, Dijsselbloem N, et al. The 
importance of a multi-disciplinary perspective and 
patient activation programmes in MS management. 
Mult Scler 2016; 22: 34–46.
 20. Otero-Romero S, Sastre-Garriga J, Comi G, et al. 
Pharmacological management of spasticity in 
multiple sclerosis: Systematic review and consensus 
paper. Mult Scler 2016; 22: 1386–1396.
 21. Brownlee WJ and Ciccarelli O. All relapsing multiple 
sclerosis patients should be managed at a specialist 
clinic – YES. Mult Scler 2016; 22: 873–875.
 22. Mattarozzi K, Baldin E, Zenesini C, et al. Effect of 
organizational features on patient satisfaction with 
care in Italian multiple sclerosis centres. Eur J Neurol 
2017; 24: 631–637.
 23. Motl RW, Sandroff BM, Kwakkel G, et al. Exercise 
in patients with multiple sclerosis. Lancet Neurol 
2017; 16: 848–856.
 24. Mohr DC, Hart SL and Goldberg A. Effects of 
treatment for depression on fatigue in multiple 
sclerosis. Psychosom Med 2003; 65: 542–547.
 25. Langer-Gould AM. The pill times 2: What every 
woman with multiple sclerosis should know. 
Neurology 2014; 82: 654–655.
 26. Marrie RA, Reingold S, Cohen J, et al. The incidence 
and prevalence of psychiatric disorders in multiple 
sclerosis: A systematic review. Mult Scler 2015; 21: 
305–317.
 27. Vermersch P, Faller A, Czarnota-Szalkowska D, et al. 
The patient’s perspective: How to create awareness 
for improving access to care and treatment of MS 
patients? Mult Scler 2016; 22: 9–17.
 28. Anderson M and Kimberly McCleary K. On the path 
to a science of patient input. Sci Transl Med 2016; 8: 
336ps311.
 29. Chiu C, Bishop M, Pionke JJ, et al. Barriers to the 
accessibility and continuity of health-care services in 
people with multiple sclerosis: A literature review. Int 
J MS Care 2017; 19: 313–321.
 30. Uygunoglu U, Kantarci O and Siva A. Integrated 
multidisciplinary clinics should be the gold standard 
in managing progressive MS – YES. Mult Scler 2016; 
22: 1126–1128.
 31. Papeix C, Gambotti L, Assouad R, et al. Evaluation 
of an integrated multidisciplinary approach in 
multiple sclerosis care: A prospective, randomized, 
controlled study. Mult Scler J Exp Transl Clin 2015; 
1: 1–8.
 32. Papeix C and Lubetzki C. Integrated multidisciplinary 
clinics should be the gold standard in managing 
progressive MS – NO. Mult Scler 2016; 22: 1128–
1130.
Visit SAGE journals online 
journals.sagepub.com/
home/msj
 SAGE journals
